France's Novacyt reports slightly higher FY 2025 revenue

Novacyt SA

21/01/2026 07:09

Overview

Molecular diagnostics firm's FY 2025 revenue growing slightly from FY 2024

Instrumentation segment grew over 25%, driven by LightBench Discover launch

Company maintained strong cash position of £19.2m, remaining debt-free

Outlook

Company anticipates growth opportunities in 2026 driven by customer interest in new technologies

Novacyt expects to launch Yourgenes Insight DPYD assay in H1 2026

Company maintains strong cash position, remains debt-free

Result Drivers

CLINICAL SEGMENT - Growth driven by acquisition of a new strategic customer in APAC region

INSTRUMENTATION GROWTH - Over 25% growth driven by LightBench Discover launch

RUO SEGMENT DECLINE - Decline due to reduced sales of Primerdesign catalogue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
GBP 20 mln


Press Release: ID:nRSU6401Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)